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Abstract
Background: Neuroleptic malignant syndrome is a rare but life-threatening idiosyncratic complication following the use of  
antipsychotic agents, anaesthesia and surgery. It is characterized by hyperthermia, muscle rigidity, autonomic disturbances and 
mental state alterations.
Case: A 31 year old female weighing 60kg received a depot preparation of  Fluphenazine on account of  depression with psy-
chotic features observed two days prior to elective Cholecystectomy under general anaesthesia. Surgery and anaesthesia were es-
sentially uneventful. Forty eight hours post-operatively, the patient developed features suggestive of  neuroleptic malignant syn-
drome complicated by aspiration pneumonitis. This necessitated her admission into the intensive care unit. She had prolonged 
stay in the intensive care unit, where she was mechanically ventilated, developed deep venous thrombosis of  the left upper limb 
and required tracheostomy on account of  prolonged endotracheal intubation. Patient recovered fully following bromocriptine 
and dantrolene  therapy. She was discharged home after 60 days on admission and has remained in good health.
Conclusion: Though rare, neuroleptic malignant syndrome can occur in young adult females following use of  antipsychotics, 
anaesthesia and surgery. Its clinical course can be prolonged and distressing with the use of  depot preparations. Early diagnosis 
and prompt supportive measures are essential to reduce morbidity and mortality.
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Neuroleptic malignant syndrome (NMS) is a rare but 
life-threatening idiosyncratic complication of  antipsy-
chotic treatment characterized by hyperthermia (fever), 
muscle rigidity, autonomic disturbances and mental state 
alterations. First described in 19681,2, shortly after the in-
troduction of  neuroleptics, it occurs in about 0.2% of  
patients3 treated with the medications (varies from 0.02% 
to 2.44%4).
Although NMS frequently develops over a 24-72 hour 
period, the risk of  developing NMS may last 10-20 days 
after discontinuation of  neuroleptics or even longer when 
associated with depot formulations5.  
There is no single diagnostic tool/test that’s been advo-
cated for the diagnosis of  NMS hence it’s often a diagno-
sis of  exclusion. Levenson1 proposed a set of  major and 
minor criteria that indicate a high probability of  NMS. 
The major category includes: fever, rigidity and elevated 
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creatine phosphokinase concentration. The minor cate-
gory includes: tachycardia, abnormal arterial pressure, 
tachypnoea, altered consciousness, diaphoresis and leu-
cocytosis. The presence of  all three major signs, or two 
major and four minor signs indicate a high likelihood of  
the presence of  NMS.
NMS commonly affects young adult males and has been 
reported in both psychiatric and medical/surgical patients 
or following preoperative use of  neuroleptic agents. It oc-
curs more commonly with the typical antipsychotics such 
as haloperidol and, to a lesser extent, following adminis-
tration of  the newer atypical antipsychotics such as depot 
fluphenazine4,6,7,8. NMS  following exposure to anaesthe-
sia and surgery has been reported in some cases9,10,11,12.
The clinical management of  NMS is largely supportive13, 
following identification and withdrawal of  the neurolep-
tic. Most patients recover completely without residual 
neurological deficits with intensive care, prompt support-
ive measures and use of  drugs such as bromocriptine, 
amantadine and dantrolene14.
This report is a case of  neuroleptic malignant syndrome 
in a young adult female following depot fluphenazine ad-
ministration, anaesthesia and surgery in University of  Be-
nin Teaching Hospital, Benin City, Nigeria.
Case description
A 31 year old female, weighing 60kg, with no history of  
psychiatric disorder, co-morbid conditions, previous sur-
gical or anaesthetic exposure, was scheduled for elective 
cholecystectomy on account of  resolved calculus chole-
cystitis. Two days prior to surgery, she was reviewed by 
the Psychiatrists on account of  poor sleep, depressed af-
fect, selective mutism, restlessness, refusal of  food/med-
ications and inappropriate speech. A diagnosis of  adjust-
ment disorder with depressive features was made and she 
was commenced on intramuscular (I.M.) Fluphenazine 
25mg stat, oral Benzhexol 5mg pro re nata (PRN) and 
oral Amitriptylline 50mg nocte. Over the next two days, 
her depressive symptoms improved but she remained 
mute.
Investigation results available, including full blood count, 
electrolytes and creatinine, were all within normal refer-
ence range. She had cholecystectomy with common bile 
duct exploration under general anaesthesia. Anaesthesia 
was induced with intravenous (I.V.) propofol 150mg and 
tracheal intubation with a size 7.5mm internal diameter, 
cuffed endotracheal tube facilitated with I.V. suxametho-
nium 100mg. Anaesthesia was maintained with isoflurane 
in oxygen-air mixture while muscle paralysis was main-
tained with I.V. atracurium. Analgesia was achieved with 
iv Paracetamol 600mg, iv Ketorolac 30mg and iv trama-
dol 60mg while surgical site was infiltrated with 20mls 
of  0.125% Bupivacaine at the end of  surgery.  Surgery, 
anaesthesia and the immediate post-op period were es-
sentially uneventful but patient was observed to be mute.
Two days post-op, patient was observed to be dyspnoeic, 
tachypnoeic, with widespread crepitations on chest aus-
cultation, having generalised tremors and muscle rigidity, 
diaphoresis and persistently febrile. Full blood count done 
revealed an elevated white blood cell count (16.2 x 103/
µl) with relative lymphopenia (11.9%) and granulocytosis 
(81.6%). Her platelet count was also elevated (536 x 103/
µl). A diagnosis of  Neuroleptic malignant syndrome with 
aspiration pneumonitis was made. All neuroleptics were 
discontinued and she was admitted into the intensive 
care unit (ICU). Following diagnosis, she was immediate-
ly commenced on bromocriptine tablets 2.5mg 8 hourly 
(via nasogastric tube) while efforts were made to procure 
parenteral Dantrolene. Active cooling with ice packs and 
refrigerated intravenous fluids was commenced. A repeat 
full blood count done on admission into the ICU showed 
a white blood cell count of  23.7 x 103/µl.
A day after admission into the ICU, her trachea was intu-
bated and she was mechanically ventilated with Synchro-
nized Intermittent Mandatory Ventilation mode, using 
the low tidal volume - high positive end-expiratory pres-
sure approach. Shortly after intubation, she was noticed 
to be hypotensive despite fluid therapy and was thus com-
menced on ionotropic support using I.V. noradrenaline 
at 0.5µg/kg/min with good response/effect. Antibiotic 
therapy as well as Deep Vein Thrombosis (DVT) prophy-
laxis were instituted and management (pharmacological 
and adjuvant) for NMS continued.
Twenty four hours after ICU admission and endotrache-
al intubation; forty eight hours after ICU admission, she 
was commenced on Dantrolene capsules 100mg 8 hourly 
(I.V. preparation could not be sourced) administered via 
the nasogastric tube. Over the next few days, with reso-
lution of  the pneumonitis, she was weaned off  the venti-
lator and also weaned off  ionotropic support. However, 
she could not be extubated (following discontinuation of  
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mechanical ventilation on the 6th day after intubation) 
because her airway reflexes were still depressed and she 
continued to drool saliva. Oxygen supplementation was 
continued via a T-piece.
After 72 hours of  Dantrolene therapy, hyper-reflexia, 
muscle hyperkinesia and tremors had reduced significant-
ly and the drug was gradually tailed off. However, a day 
after discontinuation of  the Dantrolene, the tremors were 
exarcebated and thus, she was recommenced on the med-
ication. She was extubated on the 15th day on ICU ad-
mission but had another episode of  aspiration two days 
later necessitating re-intubation and mechanical ventila-
tion. She had bedside elective tracheostomy 5 days later 
on account of  prolonged endotracheal intubation. She 
was commenced on I.V. Albumin on account of  hypo-al-
buminaemia.
On the 26th day of  ICU admission, she developed deep 
venous thrombosis of  the left upper limb despite hav-
ing been on low molecular weight heparin and regular 
physiotherapy. The limb was elevated and physiotherapy 
to that limb discontinued while dosage of  anticoagulant 
(sub-cutaneous clexane) was increased to 40mg 12 hourly 
and warfarin tablets 2.5mg nocte and had serial monitor-
ing of  clotting profile.
With improvement in symptoms, the dosage of  Dantro-
lene was gradually tailed off  and then discontinued. As 
the DVT resolved and with serial international normal-
ized ratio measurements, anticoagulation was gradually 
reduced while appropriate physiotherapy continued.
On the 35th day of  ICU admission, she was noticed to 
be progressively withdrawn and uncooperative. She was 
reviewed bythe psychiatrists and was commenced on Ser-
traline tablets 50mg daily. Three days later (43rd day post-
op, 38th day post ICU admission), she was discharged 
from the ICU and transferred to the oto-rhino-laryn-
gology ward for continued tracheostomy care (18th day 
post-tracheostomy).
She was successfully decannulated on the 31st day 
post-tracheostomy without adverse sequelae. She con-
tinued to make sustained clinical improvement and was 
discharged home after 60days on admission. Patient con-
tinues to be in good health and is being followed up in the 
clinic on out-patient basis.
Discussion
As with most rare idiosyncratic complications of  thera-
peutic interventions, diagnosis of  NMS may be delayed or 
missed altogether due to non-specific symptoms and the 
patient’s pre-morbid or co-existing medical conditions12. 
In this case, diagnosis was made early after deterioration 
of  the patient’s clinical condition post-operatively.
While the use of  a depot preparation of  antipsychotic 
medication prior to surgery may seem reasonable consid-
ering the expectation of  prolonged fasting or non-suit-
ability of  the enteral route, its use in patients without a 
previously documented history of  prior treatment with 
such medications may be called to question given the risk 
of  prolonged clinical course in the event of  the occur-
rence of  severe reactions15, as encountered in this case.
Institution of  prompt supportive care, especially in an in-
tensive care unit, has been shown to improve the outcome 
in cases of  NMS13,14. This patient may not have survived 
without such care/management. Airway compromise and 
aspiration proved to be particularly important challenges 
in this case and provision of  a definitive airway (endo-
tracheal intubation and subsequently, tracheostomy) no 
doubt proved quite beneficial in this case.
Although parenteral preparations of  dantrolene have 
been the most frequently documented option16, this case 
clearly shows that where such preparations are not avail-
able, the oral formulations administered via a nasogas-
tric tube may be equally beneficial and efficacious. After 
a prolonged and unsuccessful search for the intravenous 
preparation, we resorted to the use of  the oral prepara-
tion and achieved quite satisfactory result.
Re-institution of  antipsychotic or antidepressant medica-
tions may be particularly challenging aspects of  care of  
patients with NMS, especially during the recovery phase5. 
Reluctance to recommence any antipsychotics is an un-
derstandable reaction following the occurrence of  NMS 
but needless delays in commencing suitably selected med-
ications, especially when clearly indicated, may prolong 
the recovery and clinical course of  such patients. Where 
such indication exists, the patients and relatives need to 
be counselled on the need for commencing such medi-
cations and available options. Heightened vigilance must 
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be maintained to ensure detection of  the earliestsigns of  
relapse, in which case, the medications should be prompt-
ly discontinued17.
The care of  patients with NMS may be complicated by 
other conditions such as deep venous thrombosis due 
to prolonged immobilization18. Prompt intervention and 
management of  the deep venous thrombosis in this case 
was instrumental in ensuring a good outcome.
Conclusion
Though rare, neuroleptic malignant syndrome can occur 
in young adult females following use of  atypical antipsy-
chotics, anaesthesia and surgery. Its clinical course can be 
prolonged and distressing with the use of  depot prepa-
rations. Early diagnosis and prompt supportive measures 
are essential to reduce morbidity and mortality.
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